NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: In our continuing search for effective compounds to kill CML cells carrying T315I-Bcr-Abl [22,23], we tested this NF-κB inhibitor (pristimerin) against CML cells including those carrying T315I-Bcr-Abl, and elaborated the mechanistic detail of the inhibition of NF-κB by pristimerin.